Method of preventing or reducing scarring of human skin
AssigneePharmecosse Ltd.
InventorsClaire Linge, Ian Paul Mackie
Life of this patent
Estimating the term…
Abstract
Insulin or a peroxisome proliferator-activated receptor (PPAR) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the PPAR agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring while enhancing re-epithelialization of the wound and thus provides a dual action wound healing treatment. The present invention accordingly provides a highly effective prophylactic treatment for any individual suffering tissue trauma to reduce and/or prevent normal and/or pathological scarring.
Claims14
A method of reducing dermal scarring of a skin wound of a human compared with untreated skin, the method comprising:
- administering to the skin wound, wherein the skin wound is a burn, a composition consisting of an effective amount of insulin dissolved in a pharmaceutically acceptable liquid vehicle, wherein the composition is injected as a single injectable dose up to 2 days after the skin wound is formed.
A method of reducing dermal scarring of a skin wound of a human compared with untreated skin, the method comprising:
- administering a composition to a vicinity of the skin wound, wherein the skin wound is a burn, the composition consisting of an effective amount of insulin dissolved in a pharmaceutically acceptable diluent, wherein the composition is administered as a single injectable dose up to 2 days after the skin wound is formed.
Dependencies are inferred from the claim text.